Trelegy Ellipta Effectiveness
Chronic Obstrucive Pulmonary Disease ( COPD ) is a progressive lung disease that affects millions of people around the world . It is a complex condition characterized by persistent airflow limitation that is not fully reversible . COPD is often caused by long - term exposure to irritating particles or gases , most often from cigarette smoke . In the United States , COPD is the third leading cause of death , accounting for more than 120 , 000 deaths per year . COPD is a chronic , progressive disease that progresses slowly over time . It can occur at any age , but is most common in adults over the age of 40 who have a history of smoking or have been exposed to second hand smoke or other air pollutants. Symptoms of COPD can include short ness of breath , wheezing , and a chronic cough that produces mucus . As the disease progresses , individuals may also experience fatigue , chest tight ness , and difficulty speaking or performing normal activities . Trelegy Ellipta is a combination of three inhaled medicines that work together to help reduce symptoms of chronic obstructive pulmonary disease (COPD). It is a once-daily medication that is taken using an inhaler device. Trelegy Ellipta works by controlling inflammation in the lungs, helping to reduce and prevent flare-ups of COPD. It is available in two different dosage strengths, and can be used in combination with other COPD treatments, such as long-acting beta agonists ( LABAs ) and/or inhaled corticosteroids ( ICS ). The main active ingredients in Trelegy Ellipta are fluticasone furoate, umeclidinium, and vilanterol. Fluticasone furoate is a corticosteroid that helps to reduce inflammation in the airways. Umeclidinium is an anticholinergic that helps to reduce the activity of the muscles in the airways, which can help reduce symptoms such as wheezing and shortness of breath. Vilanterol is a long-acting beta agonist ( LABA ) that helps to open the airways and make it easier to breathe. Now, you know How Effective is Trelegy Ellipta .